Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 719

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 719
---
 this Article XII.

Section 12.4 Deemed Notice . Any person or entity purchasing or otherwise acquiring or holding any interest in any security of the Corporation shall be deemed to have notice of and consented to this Article XII .

<div align='center'>C-7</div>

TABLE OF CONTENTS

IN WITNESS WHEREOF, Iris Acquisition Corp. has caused this Amended and Restated Certificate to be duly executed and acknowledged in its name and on its behalf by an authorized officer as of the date first set forth above.

<div align='center'>C-8</div>

TABLE OF CONTENTS

#### Annex D​

#### EXECUTION VERSION​

### SPONSOR SUPPORT AGREEMENT
This SPONSOR SUPPORT AGREEMENT, dated as of November 30, 2022 (this “ Agreement ”), is entered into by and among the shareholder listed on Exhibit A hereto (the “ Shareholder ”), Liminatus Pharma, LLC, a Delaware limited liability company (the “ Company ”), and Iris Acquisition Corp, a Delaware corporation (“ SPAC ”). Capitalized terms used but not defined in this Agreement shall have the meanings ascribed to them in the Business Combination Agreement (as defined below).

WHEREAS, SPAC, the Company, Iris Parent Holding Corp., a Delaware corporation (“ ParentCo ”), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of ParentCo (“ Liminatus Merger Sub ”) and SPAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of ParentCo (“ SPAC Merger Sub ”), are or will be parties to that certain Business Combination Agreement, dated as of the date hereof (as amended, modified or supplemented from time to time, the “ Business Combination Agreement ”), which provides, among other things, that, upon the terms and subject to the conditions thereof, (i) Liminatus Merger Sub will be merged with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of ParentCo (the “ Company Merger ”), and (ii) immediately following the transaction described in (i), SPAC Merger Sub will be merged with and into SPAC, with SPAC surviving the SPAC Merger as a direct wholly owned subsidiary of ParentCo (the “ SPAC Merger ” and, together with the Company Merger, the “ Merger ”);

WHEREAS, as of the date hereof, the Shareholder owns the number of shares of Class B common stock